Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Operating Costs and Expenses:
General and administrative	$ 1,705	$ 2,095	$ 5,440	$ 6,668
Research and development	4,137	7,061	15,028	22,380
Total Operating Costs and Expenses	5,842	9,156	20,468	29,048
Loss from Operations	(5,842)	(9,156)	(20,468)	(29,048)
Other (Expense) Income:
Change in fair value of warrant liability	(5,092)	666	2,157	3,681
Interest income	4	1	7	36
Total Other (Expense) Income	(5,088)	667	2,164	3,717
Net Loss	(10,930)	(8,489)	(18,304)	(25,331)
Net Loss Attributable to Non-controlling Interest	(8)	(136)	(280)	(451)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(10,922)	(8,353)	(18,024)	(24,880)
Series A Preferred Stock Dividends	(6,901)	0	(6,901)	0
Net Loss Attributable to Common Stockholders	$ (17,823)	$ (8,353)	$ (24,925)	$ (24,880)
Net Loss Per Share - Basic and Dilutive	$ (0.14)	$ (0.09)	$ (0.20)	$ (0.27)
Weighted average number of shares outstanding during the period - Basic and Dilutive	128,279,674	91,441,687	122,950,397	91,095,990